Shanghai Fosun Pharmaceutical (02196) said its profit attributable to owners of the parent for the six months ended 30 June 2018 dropped 7.61% year-on-year to RMB1,560 million.
Basic and diluted earnings per share were RMB63 cents.
Revenue amounted to RMB11,767 million, an increase of 42.2% from a year earlier.
No interim dividend will be distributed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.